Five Eleven Pharma Inc.

Zhihao Zha

Hank F Kung

Seok Rye Choi

Zehui Wu

Karl Ploessl

Futao Liu

Karl Plössl

The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.

Deuterium substituted positron emission tomography (PET) imaging agents and their pharmacological application

The present invention relates to compounds according to Formula I and Formula IV. These compounds display very good binding affinities to the PSMA binding sites. They can be labeled with [Ga]GaClwith high yields and excellent radiochemical purity. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I or Formula IV, or a pharmaceutically acceptable salt thereof.

Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy

The present invention relates to compounds according to Formula I or Formula II, which are potential bone imaging agents. Certain compounds labeled withGa displayed excellent bone uptake and retention. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I or Formula II or a pharmaceutically acceptable salt thereof. 

Growing community of inventors

Philadelphia, PA, United States of America

Zhihao Zha